Patent intelligence · US
US 7608714
Production of dolasetron
Production of dolasetron
Patent details — US 7608714
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 27, 2009
- Expiration
- Oct 22, 2029
- Claims
- 80
- CPC classes
- A61P, A61P25/06
Quick answer
US 7608714 (Production of dolasetron) is held by TEVA Gyógyszergyár Zártkörüen Müködö Részvénytárasaság. Status: granted. Granted Oct 27, 2009. Expires Oct 22, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 80
- CPC classes
- A61P, A61P25/06
More from TEVA Gyógyszergyár Zártkörüen Müködö Részvénytárasaság
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 7608714?
US 7608714 (Production of dolasetron) is held by TEVA Gyógyszergyár Zártkörüen Müködö Részvénytárasaság. Status: granted. Granted Oct 27, 2009. Expires Oct 22, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7608714?
TEVA Gyógyszergyár Zártkörüen Müködö Részvénytárasaság is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 7608714 expire?
Our index shows an expiration date of Oct 22, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.